Scipher Discloses 10.4% Chemomab Stake After $1.1M Note-Funded ADS Purchase
CMMB sits 46% above its 52-week low of $0.92.
Summary
Scipher reported a 10.4% stake in Chemomab after buying 932,203 ADSs at $1.18 for about $1.1M — a purchase required by the merger agreement and funded largely by $858,612 of Scipher's own convertible notes.
Key Events · Ownership and Investor Activity · CMMB
-
Scipher Reports 10.4% Chemomab Stake
Scipher Medicine beneficially owns 74,576,240 ordinary shares (932,203 ADSs), or approximately 10.4% of the 643,889,200 shares outstanding as of October 29, 2026.
-
$1.1M Purchase Funded by Scipher Notes
Scipher paid about $1.1M ($1.18 per ADS) using $858,612 of proceeds from October Notes sold to seven investors plus roughly $241,387 of working capital.
-
Notes Convert at Merger Closing
The Notes mature August 5, 2027 and are satisfied at closing with Chemomab Parent shares equal to principal divided by $1.18, times the Domestication Exchange Ratio; if the merger terminates, the Notes stay outstanding and Scipher keeps the ADSs.
-
Purchase Was Contractually Required
Section 5.6 of the July 7, 2026 merger agreement obligated Scipher to fund up to $1.1M after Chemomab's October 11 financing notice; Chemomab consented to the bridge notes on November 3.
Analysis · CMMB · Life Sciences
Scipher, the merger counterparty, now holds 74,576,240 Chemomab ordinary shares (932,203 ADSs) — a 10.4% stake — bought at $1.18 per ADS on November 3. The purchase was contractually required: Section 5.6 of the July 7 merger agreement obliges Scipher to fund up to $1.1M if Chemomab needs cash before closing, and Chemomab delivered a $1.1M financing notice on October 11. Scipher raised $858,612 of the price by issuing October Notes to its own investors and covered the rest from working capital. The stake is effectively escrowed for those noteholders: at closing, the Notes are cancelled in exchange for the Chemomab Parent shares and CVRs generated by the ADSs. If the merger terminates, the Notes stay outstanding and Scipher keeps the ADSs. The practical read is that the acquirer is financing the target's runway, and the 10.4% block is committed merger consideration rather than open-market conviction. The December 4 special meeting vote remains the gating event.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMMB was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.92 to $2.99. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.